These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 3260924)

  • 41. Interleukin 2 induces human acute lymphocytic leukemia cells to manifest lymphokine-activated-killer (LAK) cytotoxicity.
    Kaufmann Y; Levanon M; Davidsohn J; Ramot B
    J Immunol; 1987 Aug; 139(3):977-82. PubMed ID: 3496395
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: effect of tumor necrosis factor alpha and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity.
    Owen-Schaub LB; Gutterman JU; Grimm EA
    Cancer Res; 1988 Feb; 48(4):788-92. PubMed ID: 3257408
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lymphokine-activated killer cells. VII. IL-4 induces an NK1.1+CD8 alpha+beta- TCR-alpha beta B220+ lymphokine-activated killer subset.
    Ballas ZK; Rasmussen W
    J Immunol; 1993 Jan; 150(1):17-30. PubMed ID: 7678028
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Endogenous and adoptively transferred A-NK and T-LAK cells continuously accumulate within murine metastases up to 48 h after inoculation.
    Hokland M; Kjaergaard J; Kuppen PJ; Nannmark U; Agger R; Hokland P; Basse P
    In Vivo; 1999; 13(3):199-204. PubMed ID: 10459491
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inhibition of lymphokine-activated killer cell-mediated cytotoxicity by phorbol ester.
    Nishimura T; Burakoff SJ; Herrmann SH
    J Immunol; 1989 Mar; 142(6):2155-61. PubMed ID: 2646377
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Lymphokine-activated killer (LAK) cell phenomenon. IV. Lysis by LAK cell clones of fresh human tumor cells from autologous and multiple allogeneic tumors.
    Rayner AA; Grimm EA; Lotze MT; Wilson DJ; Rosenberg SA
    J Natl Cancer Inst; 1985 Jul; 75(1):67-75. PubMed ID: 2989604
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
    Papa MZ; Mulé JJ; Rosenberg SA
    Cancer Res; 1986 Oct; 46(10):4973-8. PubMed ID: 3489517
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice.
    Shiloni E; Lafreniere R; Mulé JJ; Schwarz SL; Rosenberg SA
    Cancer Res; 1986 Nov; 46(11):5633-40. PubMed ID: 3489526
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Leu-11+ lymphocytes with natural killer (NK) activity are precursors of recombinant interleukin 2 (rIL 2)-induced activated killer (AK) cells.
    Itoh K; Tilden AB; Kumagai K; Balch CM
    J Immunol; 1985 Feb; 134(2):802-7. PubMed ID: 3917475
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lymphokine-activated killer cells in rats. IV. Developmental relationships among large agranular lymphocytes, large granular lymphocytes, and lymphokine-activated killer cells.
    Maghazachi AA; Vujanovic NL; Herberman RB; Hiserodt JC
    J Immunol; 1988 Apr; 140(8):2846-52. PubMed ID: 3258622
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Characteristics of murine non-specific killer cells induced in vivo by recombinant human interleukin-2.
    Hinuma S; Naruo K; Shiho O; Tsukamoto K
    Immunology; 1986 Oct; 59(2):251-9. PubMed ID: 3490435
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Synergistic effect of Nocardia rubra cell wall skeleton and recombinant interleukin 2 for in vivo induction of lymphokine-activated killer cells.
    Miyazaki K; Yasumoto K; Yano T; Matsuzaki G; Sugimachi K; Nomoto K
    Cancer Res; 1991 Oct; 51(19):5261-5. PubMed ID: 1833049
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Enhancement of murine lymphokine-activated killer cell activity by retinoic acid.
    Lin TH; Chu TM
    Cancer Res; 1990 May; 50(10):3013-8. PubMed ID: 1970751
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Transforming growth factor-beta 1 (TGF-beta 1) and recombinant human tumor necrosis factor-alpha reciprocally regulate the generation of lymphokine-activated killer cell activity. Comparison between natural porcine platelet-derived TGF-beta 1 and TGF-beta 2, and recombinant human TGF-beta 1.
    Espevik T; Figari IS; Ranges GE; Palladino MA
    J Immunol; 1988 Apr; 140(7):2312-6. PubMed ID: 3280680
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A rat anti-mouse T4 monoclonal antibody (H129.19) inhibits the proliferation of Ia-reactive T cell clones and delineates two phenotypically distinct (T4+, Lyt-2,3-, and T4-, Lyt-2,3+) subsets among anti-Ia cytolytic T cell clones.
    Pierres A; Naquet P; Van Agthoven A; Bekkhoucha F; Denizot F; Mishal Z; Schmitt-Verhulst AM; Pierres M
    J Immunol; 1984 Jun; 132(6):2775-82. PubMed ID: 6202760
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Expression and function of LFA-1 on A-NK and T-LAK cells: role in tumor target killing and migration into tumor tissue.
    Donskov F; Basse PH; Hokland M
    Nat Immun; 1996-1997; 15(2-3):134-46. PubMed ID: 9162263
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Generation of lymphokine-activated killer cells in strain 2 guinea pigs and their use in the therapy of L2C, an acute B-cell leukemia.
    Gregg EO; Gregg IC; Green I
    Cancer Res; 1987 Feb; 47(3):723-9. PubMed ID: 3492265
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Characteristics of mouse thymocyte-derived, interleukin 2-activated killer cells and their precursors.
    Yagi H; Nishimura T; Hashimoto Y
    Jpn J Cancer Res; 1987 Jul; 78(7):721-8. PubMed ID: 3114198
    [TBL] [Abstract][Full Text] [Related]  

  • 59. T cell nature of some lymphokine-activated killer (LAK) cells. Frequency analysis of LAK precursors within human T cell populations and clonal analysis of LAK effector cells.
    Moretta L; Pende D; Cozzani R; Merli A; Bagnasco M; Mingari MC
    Eur J Immunol; 1986 Dec; 16(12):1623-5. PubMed ID: 3102249
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Lymphokine-activated killer (LAK) cells. IV. Characterization of murine LAK effector subpopulations.
    Ballas ZK; Rasmussen W
    J Immunol; 1990 Jan; 144(1):386-95. PubMed ID: 2104892
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.